Oxford BioDynamics PLC (GB:OBD)
LSE:OBD
Want to see GB:OBD full AI Analyst Report?
OBD Stock Chart & Stats
0.24 p
0.04 p(3.63%)
At close: 4:00 PM EST
0.24 p
0.04 p(3.63%)
Day’s Range― - ―
52-Week Range0.16 p - 0.78 p
Previous CloseN/A
Volume22.58K
Average Volume (3M)21.87M
Market Cap
£7.23M
Enterprise Value7.66M
Total Cash (Recent Filing)£1.39M
Total Debt (Recent Filing)£5.11M
Price to Earnings (P/E)―
Beta-0.39
Next Earnings
Jan 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding4,290,911,000
10 Day Avg. Volume50,883,470
30 Day Avg. Volume21,870,725
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.90
Price to Sales (P/S)6.02
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£2.32M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line growth (noted at 22.21%) signals commercial traction for EpiSwitch tests and services. Over 2–6 months this supports scaling revenue base, improves leverage on fixed R&D costs, and increases the chance of converting pilot customers into recurring service and licensing contracts.
Proprietary PlatformThe EpiSwitch® platform is a differentiated, proprietary technology that analyzes 3D genomic conformations. This scientific differentiation creates a durable competitive advantage for diagnostic discovery, supports high-value assay development, and underpins licensing and partnership opportunities over the medium term.
Diversified Revenue ModelA multi-stream business model (own test commercialization, fee-for-service biomarker work, and potential licensing/milestones) creates durable revenue flexibility. Service contracts can provide near-term cash and partner deals can fund validation and distribution, reducing reliance on a single product launch cycle.
Bears Say
High LeverageA debt/equity of 4.58 indicates substantial leverage that constrains strategic choices. Over months this raises refinancing and covenant risks, increases interest burden, and limits the company's ability to invest in trials, commercial roll-out, or absorb delayed reimbursements without dilutive financing.
Negative ProfitabilityConsistent negative gross, EBIT and net margins (-10.19% net) show the business hasn’t yet achieved cost structures that support profitable diagnostics. Persistent losses erode equity, force ongoing capital raises, and make it harder to fund regulatory and commercialization activities from internal cash generation.
Weak Cash GenerationA -33.93% decline in free cash flow growth and negative operating cash flow relative to net income indicate worsening cash conversion. This reduces runway, increases dependence on external financing, and limits the firm's ability to support multi-center studies or scale lab operations without dilutive or costly funding.
Oxford BioDynamics News
OBD FAQ
What was Oxford BioDynamics PLC’s price range in the past 12 months?
Oxford BioDynamics PLC lowest share price was 0.16 p and its highest was 0.78 p in the past 12 months.
What is Oxford BioDynamics PLC’s market cap?
Oxford BioDynamics PLC’s market cap is £7.23M.
When is Oxford BioDynamics PLC’s upcoming earnings report date?
Oxford BioDynamics PLC’s upcoming earnings report date is Jan 26, 2027 which is in 236 days.
How were Oxford BioDynamics PLC’s earnings last quarter?
Currently, no data Available
Is Oxford BioDynamics PLC overvalued?
According to Wall Street analysts Oxford BioDynamics PLC’s price is currently Overvalued.
Does Oxford BioDynamics PLC pay dividends?
Oxford BioDynamics PLC does not currently pay dividends.
What is Oxford BioDynamics PLC’s EPS estimate?
Oxford BioDynamics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oxford BioDynamics PLC have?
Oxford BioDynamics PLC has 4,290,911,000 shares outstanding.
What happened to Oxford BioDynamics PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Oxford BioDynamics PLC?
Currently, no hedge funds are holding shares in GB:OBD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oxford BioDynamics PLC
Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and internationally. The company provides EpiSwitch, a proprietary technology platform for the discovery, evaluation, validation, and monitoring of epigenetic biomarkers known as chromosome conformation signatures for use in medical testing kits, disease prediction, diagnosis, and treatment. Its products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic test for predicting response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling and biomarker discovery. Oxford BioDynamics Plc was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.
Technical Analysis
IXICO plc
―
SkinBioTherapeutics
―
Fusion Antibodies Plc
―
Genflow Biosciences Plc
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---